Cationic immune complex arthritis in mice--a new model. Synergistic effect of complement and interleukin-1 - PubMed (original) (raw)

. 1992 Jun;140(6):1451-61.

Affiliations

• PMID: 1605310
• PMCID: PMC1886551

Cationic immune complex arthritis in mice--a new model. Synergistic effect of complement and interleukin-1

P L van Lent et al. Am J Pathol. 1992 Jun.

Abstract

A novel cationic immune-complex-mediated arthritis (ICA) model was developed in mice. The highly cationic protein lysozyme was coupled to poly-L-lysine (PLL) and injected intra-articularly into the knee joint of the mouse, shortly after systemic administration of specific antibodies. A vehement joint inflammation developed, characterized by severe joint swelling and the influx of predominantly polymorphonuclear (PMN) leukocyte. Unique properties were combined in this protein. First, an excellent retention of the antigen in joint structures was found, facilitating sufficient IC formation in the synovial tissue and at the cartilage surface. Secondly, PLL.lysozyme appeared to be a potent inducer of interleukin-1 (IL-1). Similar IL-1 production was measured at 6 hours, in both immune or nonimmune mice. Neutralization with antibodies against either IL-1 alpha or IL-1 beta revealed that IL-1 alpha was the dominant cytokine. Resident cells were responsible for this IL-1 production since a comparable IL-1 signal was measured after intra-articular injection of PLL.lys in neutropenic mice. We further investigated whether IL-1 and complement factors were involved in the onset of this ICA. Neutralizing the IL-1 production with antibodies directed against IL-1 alpha and beta showed a significant decrease in joint swelling. Complement depletion by cobra venom factor also prevented the onset of arthritis for the greater part. Only a minor swelling remained at 6 hours after eliciting arthritis, which was similar to the swelling after injecting the antigen alone and probably reflects IL-1 mediated inflammation. In this study, the authors show a synergistic action of IL-1 and complement in the onset of cationic ICA. Unique properties of the antigen such as excellent retention and its ability to induce IL-1 are combined within one molecule and make this antigen arthritogenic in the presence of antibodies and complement activation.

PubMed Disclaimer

Similar articles

• Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice.
  Van Lent PL, Van De Loo FA, Holthuysen AE, Van Den Bersselaar LA, Vermeer H, Van Den Berg WB. Van Lent PL, et al. J Rheumatol. 1995 Dec;22(12):2250-8. J Rheumatol. 1995. PMID: 8835558
• Immune complexes, but not streptococcal cell walls or zymosan, cause chronic arthritis in mouse strains susceptible for collagen type II auto-immune arthritis.
  Blom AB, van Lent PL, Holthuysen AE, van den Berg WB. Blom AB, et al. Cytokine. 1999 Dec;11(12):1046-56. doi: 10.1006/cyto.1999.0503. Cytokine. 1999. PMID: 10623430
• Early cartilage degradation in cationic immune complex arthritis in mice: relative role of interleukin 1, the polymorphonuclear cell (PMN) and PMN elastase.
  van Lent PL, van den Hoek AE, van den Bersselaar LA, van de Loo FA, Eykholt HE, Brouwer WF, van de Putte LB, van den Berg WB. van Lent PL, et al. J Rheumatol. 1994 Feb;21(2):321-9. J Rheumatol. 1994. PMID: 8182644
• A role for the complement system in rheumatoid arthritis.
  Low JM, Moore TL. Low JM, et al. Curr Pharm Des. 2005;11(5):655-70. doi: 10.2174/1381612053381936. Curr Pharm Des. 2005. PMID: 15720280 Review.
• Immune mediated cartilage destruction.
  Jasin HE. Jasin HE. Scand J Rheumatol Suppl. 1988;76:111-6. doi: 10.3109/03009748809102960. Scand J Rheumatol Suppl. 1988. PMID: 2908010 Review.

Cited by

• Liposomal targeting of prednisolone phosphate to synovial lining macrophages during experimental arthritis inhibits M1 activation but does not favor M2 differentiation.
  Hofkens W, Schelbergen R, Storm G, van den Berg WB, van Lent PL. Hofkens W, et al. PLoS One. 2013;8(2):e54016. doi: 10.1371/journal.pone.0054016. Epub 2013 Feb 28. PLoS One. 2013. PMID: 23468840 Free PMC article.
• Involvement of IL-6, apart from its role in immunity, in mediating a chronic response during experimental arthritis.
  de Hooge AS, van De Loo FA, Arntz OJ, van Den Berg WB. de Hooge AS, et al. Am J Pathol. 2000 Dec;157(6):2081-91. doi: 10.1016/S0002-9440(10)64846-8. Am J Pathol. 2000. PMID: 11106580 Free PMC article.
• Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment.
  van den Berg WB, Joosten LA, Helsen M, van de Loo FA. van den Berg WB, et al. Clin Exp Immunol. 1994 Feb;95(2):237-43. doi: 10.1111/j.1365-2249.1994.tb06517.x. Clin Exp Immunol. 1994. PMID: 8306498 Free PMC article.
• In vivo role of phagocytic synovial lining cells in onset of experimental arthritis.
  Van Lent PL, Van den Hoek AE, Van den Bersselaar LA, Spanjaards MF, Van Rooijen N, Dijkstra CD, Van de Putte LB, Van den Berg WB. Van Lent PL, et al. Am J Pathol. 1993 Oct;143(4):1226-37. Am J Pathol. 1993. PMID: 8214013 Free PMC article.
• Comparison of the suppressive effects of soluble CR1 and C5a receptor antagonist in acute arthritis induced in rats by blocking of CD59.
  Mizuno M, Nishikawa K, Morgan BP, Matsuo S. Mizuno M, et al. Clin Exp Immunol. 2000 Feb;119(2):368-75. doi: 10.1046/j.1365-2249.2000.01127.x. Clin Exp Immunol. 2000. PMID: 10632677 Free PMC article.

References

1. 1. Arthritis Rheum. 1990 Feb;33(2):253-60 - PubMed
2. 1. Scand J Rheumatol. 1985;14(3):239-51 - PubMed
3. 1. Nature. 1962 May 5;194:495-6 - PubMed
4. 1. Cytokine. 1989 Nov;1(1):2-13 - PubMed
5. 1. Clin Exp Immunol. 1992 Feb;87(2):196-202 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal